Effect of colon cancer sidedness compared to tumor biology on stage-specific survival.

Authors

null

Ahmed Dehal

John Wayne Cancer Institute, Santa Monica, CA

Ahmed Dehal , Brooke Vuong , Amanda N Graff-Baker , Jihey Lee , Anton Bilchik , Melanie R Goldfarb

Organizations

John Wayne Cancer Institute, Santa Monica, CA

Research Funding

Other

Background: Recent studies have reported a survival difference between right colon cancer (RCC) and left colon cancer (LCC) but were limited by lack of data on surgical therapy and underlying tumor biology including microsatellite instability (MSI) status. Our objective was to examine the influence of tumor sidedness on stage-specific survival after adjustment for those factors using a large national database. Methods: Adult patients with primary invasive colon cancer were identified from the National Cancer Data Base (NCDB) between 2009 and 2012. Cecum, ascending colon, hepatic flexure, and transverse colon were classified as “RCC” and sigmoid, descending colon, and splenic flexure were classified as “LCC”. Differences in 3-year overall survival (OS) between RCC versus LCC, stratified by stage, were obtained. Results: Of 24,092 patients, 9,095 (37.75%) presented with a LCC and 14,997 (62.25%) with a RCC. After adjustment for confounding factors, including demographics, MSI, KRAS, nodal retrieval and treatment, patients with RCC stage I, III, or IV had a 31-35% decreased OS compared to those with a LCC. However, in patients with stage II disease, RCC had a 15% improvement in OS compared to LCC (Table 1). MSI positivity was not significantly different in RCC versus LCC stage for stage nor did it contribute to decreased OS for either side. Conclusions: Colon cancer sidedness is an independent risk factor for decreased survival after adjusting for potential confounders including tumor biology and treatment characteristics. For patients with stage I, II, and IV disease, RCC portends a decreased survival compared to LCC, whereas the opposite is true for patients with stage II disease. Further research is needed to elucidate the exact the role of sidedness in risk-profiling and staging for colon cancer patients.

Overall survival outcome by stage among patients with RCC versus LCC.

Tumor stageUnadjusted
Adjusted
HR (95% C.I.)P valueHR (95% C.I.)P value
Stage I1.6 (1.2-2.0)0.00021.35 (1.05-1.75)0.02
    LCC (ref)
    RCC
Stage II1.1 (1.0-1.2)0.1620.85 (0.73-0.97)0.01
    LCC (ref)
    RCC
Stage III1.8 (1.6-2.0)< 0.00011.31 (1.17-1.48)< 0.0001
    LCC (ref)
    RCC
Stage IV1.75 (1.58-1.93)< 0.00011.34 (1.20-1.49)< 0.0001
    LCC (ref)
    RCC

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Prevention, Diagnosis, and Screening

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 543)

DOI

10.1200/JCO.2017.35.4_suppl.543

Abstract #

543

Poster Bd #

B3

Abstract Disclosures

Similar Abstracts